Ballentine Partners, LLC Intellia Therapeutics, Inc. Put Options Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NTLA
# of Institutions
341Shares Held
97MCall Options Held
1.66MPut Options Held
1.05M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$170 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$142 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$125 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$53.8 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$52.8 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $993M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...